Based on the Arch Biopartners Inc stock forecast from 0 analysts, the average analyst target price for Arch Biopartners Inc is not available over the next 12 months. Arch Biopartners Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Arch Biopartners Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Arch Biopartners Inc’s stock price was CAD 2.38. Arch Biopartners Inc’s stock price has changed by +0.42% over the past week, +8.18% over the past month and +10.70% over the last year.
No recent analyst target price found for Arch Biopartners Inc
No recent average analyst rating found for Arch Biopartners Inc
Company Overview Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals. Arch Biopartners Inc. is based in Toronto, Canada. Address: 27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5 Read Less
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 ...Read More
N/A
N/A
0
N/A
CAD
Canada
Adjusted Closing Price for Arch Biopartners Inc (ARCH:CA)
Loading...
Unadjusted Closing Price for Arch Biopartners Inc (ARCH:CA)
Loading...
Share Trading Volume for Arch Biopartners Inc Shares
Loading...
Compare Performance of Arch Biopartners Inc Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for ARCH:CA
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Arch Biopartners Inc (Sector: Biotechnology )
Frequently Asked Questions About Arch Biopartners Inc (ARCH:CA) Stock
Stock Target Advisor's fundamental analysis for Arch Biopartners Inc's stock is Neutral.
Unfortunately we do not have enough data on ARCH:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ARCH:CA's stock to indicate what its average analyst target is.
ARCH:CA stock's Price/Earning ratio is 220.00.
Our analysis grades ARCH:CA stock's Price / Earning ratio at F. This means that ARCH:CA stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the TSV exchange.
Based on this ARCH:CA may be a overvalued for its sector.
The last closing price of ARCH:CA's stock was CAD 2.38.
The most recent market capitalization for ARCH:CA is CAD 0.15B.
Unfortunately we do not have enough analyst data on ARCH:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Arch Biopartners Inc's stock.
As per our most recent records Arch Biopartners Inc has 0 Employees.
Sorry we do not have any infomation available on Arch Biopartners Inc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARCH:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
